Bright Minds Biosciences Provides Clinical Program Updates
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia
Globe Newswire27-02-2023, 18:53
Pearson VUE’s 2023 Value of IT Certification Candidate Report highlights the importance of certification for career progression in a post-pandemic era 1-02-2023, 13:05